Continuous innovation in the healthcare sphere tends to drive enhanced research potentials for gaining an edge in clinical diagnosis, and biochemical evaluations. Healthcare professionals are going above and beyond by performing consistent clinical efforts towards bettering disease diagnosis in a bid to deliver efficient patient care to individuals. Laboratory experiments, including immunoassay tests, influence majority of medical decisions. Biotin interference results in inaccurate outcomes, amplifying the risk of irrelevant and irreversible treatment. As a consequence, immunoassay interference blockers are an ideal solution aligning with the persisting technological developments and increasing demand for better evaluation.

Concerns regarding chronic diseases have been hovering around the globe since decades. The dire need for effective and accurate medical results to prevent or cure chronic illnesses is paving way for immunoassay interference blockers, such as antibody interference blockers and detection interference blockers. Further, immunoassay interference blocker reagents and kits based on human or animal serum have been witnessing boom since the past decade.

As per the new business intelligence study by Persistence Market Research, the immunoassay interference blocker market is estimated to generate a revenue of ~US$ 210 Mn in 2019 and is spectated to progress at a CAGR of ~6.5% during the stipulated timeframe 2019-2027. Escalating prevalence of chronic diseases, as well as increasing geriatrics across the globe primarily drive the need for biochemical analysis for the control of chronic diseases. In addition, the uptick in elderly cohort is observed to boost the demand for diagnostic kits and reagents for detecting age-related, as well as other chronic issues, which is set to propel the immunoassay interference blocker market.

Antibody Interference Blockers Majorly Influence the Healthcare Sector

Unwelcome cross-reactivity is one of the major factors of interferences in diagnostic immunoassays. Heterophilic antibodies (antibodies reacting with other antigens instead of its respective antigen), such as rheumatic factors, and human-anti-mouse-antibodies (HAMA), result in subpar outcomes.

Antibody interference blockers – a formulation of highly pure immunoglobulins (IgGs) – are particularly targeted against human anti-species antibodies actions. Legacy interference blockers, including, mouse serum, mouse lgG, goat serum, and goat lgG, are efficient in partial elimination of interference. Antibody interference blockers incorporate active and passive blocking agents, where the former exhibits good affinity for heterophilic antibodies.

With antibody interference blockers, false-positive or false-negative outcomes are countered, thereby improving the quality of diagnostic immunoassays. Further, the antibody interference blockers are formulated into the sample diluent at different concentrations to create the working concentration for each antibody pair.

The US and China Offer Eye-Catching Opportunities to Market Players

Manufacturers of immunoassay interference blocker are centering their focus on The US and China following rising incidents of chronic diseases. Majority of individuals in the US suffer from at least one chronic disease, including heart disease and stroke, cancer, or diabetes. In addition, chronic diseases top the list of the leading causes of mortality and abnormality in the country.

Request For Report Sample:

Chronic diseases – ischemic heart disease, and lung cancer – represent the major reasons behind premature demises in China, according to a study. As a consequence, the frequency of molecular diagnosis increases, driving the demand for immunoassay interference blocker reagents and kits from biotechnology industry, and medical settings.

Leave a comment

Your email address will not be published. Required fields are marked *